Phase 2
Breast Cancer Clinical Trial
Recruiting
Recruiting
Recruiting
Recruiting
Estimated trial completion date
Nov 1, 2031
PREDICT-RD
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery.
Patients are eligible if they are/have:
Written informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information.
- Participant is willing and able to comply with study procedures based on the judgment of the investigator.
- Age ≥ 18 years at the time of consent.
- Histological confirmation of TNBC defined by ER/PR <10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative.
- Stage II/III TNBC treated with neoadjuvant systemic therapy AND have residual disease defined as RCB II/III at time of surgery.
- Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of metastatic disease.
- The participant must have archival diagnostic tissue and/or surgical resection tissue Available.
- Participants are willing and able to comply with study procedures based on the judgment of the investigator.